More Data Is Needed To Let Biomarkers Achieve Their Potential
Although peoples understanding of biomarkers and their ability to have a profound
impact on the world of medical research and drug development continues to grow, faster progress can only be realised with more data.
There is no doubt that the benefits of utilising biomarkers in the research sector have been noted by professionals in countries across the world and they have arguably become one of the most important advances in pharmaceutical development. It is now important to keep progressing by continuing to integrate biomarkers into the process of drug development in order to gather fresh data and evidence.
There are innovative companies out there that are now fully committed to using biomarkers to aid research efforts, from the small laboratories to large multinational companies like GlaxoSmithKline. There is no doubt that progress is being made and advances are a reality, but more companies need to adopt the use of biomarkers in their research efforts in order for them to achieve regulatory status, which allows them to be used as evidence in the decision making processes during clinical trials.
Thankfully, the benefits that biomarkers can bring to research and drug development continue to be recognised more widely. This should result in a larger number of voices across the industry calling for more research, which should in turn lead to a greater amount of validated biomarker information.
Companies will be understandably keen to exploit the cost saving advantages that the use of biomarkers can bring, helping to speed up research processes and lower attrition rates at the later stages which can potentially save firms considerable sums of money. Of course it is also critical to remember the clear benefits to patients, as proven drugs are able to come to market faster than ever before. Biomarkers can play a key part in making advances in drug research, as long as there is an innovative approach to clinical development programmes.
The impact of biomarkers on the pharmaceutical research sector will undoubtedly continue to grow over the coming years as more organisations fully appreciate the potential they have to push new boundaries and dramatically improve efficiency within the laboratory environment.